Axsome Therapeutics, Inc. announced that AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the ACCORD Phase 3. | November 29, 2022
Share on Facebook Share on Twitter By Jordan Burton (For OzarksSportsZone.com) Few coaches in the Ozarks have earned as many wins as Jacky Payne, who enters his 40th season with 638 wins, 69 of which have come